Whole Breast Irradiation: Class vs. Hypofractionation
|
|
- Cassandra Quinn
- 6 years ago
- Views:
Transcription
1 Whole Breast Irradiation: Class vs. Hypofractionation Kyung Hwan Shin, MD, PhD. Dept. of Radiation Oncology, Seoul National University Hospital GBCC
2 Treatment Trends of Early Breast Cancer Less surgery lumpectomy vs mastectomy sentinel LNB vs axillary dissection Less radiation partial breast irradiation vs whole breast irradiation omitting RT (old age) hypofractionation Less chemotherapy determining who doesn t benefit from chemo by molecular subtypes or alternative molecular profiling schema (Oncotype-DX, Mammaprint, PAM50, etc)
3 Whole breast radiotherapy 50 Gy / 25 fx (± boost) - the most world wide frequent schedule - has been considered as standard fractionation
4 Prospective randomized trials comparing Lumpectomy Alone vs. with WBRT Trial N F/U (yr) op Breast recurrence (%) BCS BCS + RT % reduction Sweden Q Milan III Q NSABP-B L Ontario L Scottish L England 399 >5 L Finland L NSABP-B L * 83 * Patients received tamoxifen
5 EBCTCG, Meta-analysis EBCTCG Lancet 378: , 2014
6 Post-operative Breast Irradiation Daily fractional dose (Gy) RT Volume Total RT duration Conventional whole breast Gy Whole breast 6-7 weeks Accelerated whole breast (AWBI) (Hypofractionated) Gy Whole breast 3-4 weeks Accelerated partial breast (APBI) 3.8 bid-6 Gy qd Partial breast 1 week
7 Adjuvant radiation therapy options after breast conserving surgery
8 Post-operative Breast Irradiation Daily fractional dose (Gy) RT Volume Total RT duration Conventional whole breast Gy Whole breast 6-7 weeks Accelerated whole breast (AWBI) (Hypofractionated) Gy Whole breast 3-4 weeks Accelerated partial breast (APBI) 3.8 bid-6 qd Gy Partial breast 1 week
9 Hypofractionated RT 1) Shorter total treatment time 2) More convenient for patient ( time and money ) 3) Less resource intensive At least treatment outcome, normal tissue effect and cometic outcome should be non-inferior to standard fractionation.
10 RCT s: Treatment Scheme Fisher et al. J Clin Oncol 2014;32:
11 Equivalent local control to standard fractionation Total dose(gy) / fractionation Daily dose /total weeks 5yr local recurrence (%) 10yr local recurrence (%) RMH/GOC 50/25 39/ /13 2Gy/5wks 3Gy/5wks 3.3Gy/5wks START A 50/25 39/ /13 2Gy/5wks 3Gy/5wks 3.2Gy/5wks START B 50/25 40/15 2Gy/5wks 2.67Gy/3wks Canadian 50/ /16 2Gy/5wks 2.66Gy/3.5wks
12 Cumulative risk of LR Overall Survival Whelan TJ, NEJM 362:513-20, 2010
13 Canadian Trial: Late Toxicity Whelan et al. N Engl J Med 2010;362:
14 Canadian Trial: Cosmesis Whelan et al. N Engl J Med 2010;362:
15 Cumulative risk of LRR Disease Free Survival Haviland JS, Lancet Oncol 14: , 2013
16 Late normal tissue effect and cosmetic factors START A START B 40Gy/15fx seems gentler than 50Gy/25fx. Haviland JS, Lancet Oncol 14: , 2013
17 Late adverse effects of START-A, B START-A (%) START-B (%) 50Gy 41.6Gy 39Gy Total 50Gy 40Gy Total Symptomatic rib fracture Symptomatic lung fibrosis Ischemic heart disease (left sided) Haviland JS, Lancet Oncol 14: , 2013
18 Meta-analysis a) LR (p = 0.74) b) LRR (p = 0.32) c) Cancer-related mortality (p = 0.97) BCRT 162: , 2017
19 a) Risk of acute toxicity (p = ) b) Cosmesis (p=0.55) BCRT 162: , 2017
20 Linear-Quadratic (LQ) model for radiotherapy S=e - D- D2
21 Survival / ratio linear ( ) and the quadratic ( ) component of cell killing are equal. D= D 2 D D 2 Dose / ratio: shape of cell survival curve, BED (biological effective dose)
22 Therapeutic ratio of tumor and normal tissue 2 Gy 4 Gy Daily dose Tumor SF Normal tissue SF Therapeutic ratio 2Gy More kill Less damage better 4Gy Less kill More damage poorer
23 α/β ratio of Breast α/β ratio, Gy Conventional Tumor Normal tissue effect 10 3 In vitro human breast ca. cell lines 4 *Locoregional tumor control Change in photographic breast appearance *Bentzen SM. Lancet Oncol 9:331-41, 2008
24 α/β ratio of breast cancer (from 4 key randomized trials) Outcome RMH/GOC RMH/GOC + START A (5yr) START A (10yr F/U) RMH/GOC + START A (10yr) Local Recurrence Breast appearance (Any change) Breast Induration Telangiectasia cf. (α/β ratio 10 for other tumor tissues) Kim et al. ROJ 2016
25 Breast cancer 2 Gy 3 Gy α/β ratio of breast cancer: 4.6 Gy breast normal tissue: 3.4 Gy Breast cancer is as sensitive to fraction size as the dose-limiting normal tissues.
26 Actually, EQD2 of AWBI was less than conventional regimen Benjamin D Smith, ASTRO 2017
27 All three regimens on flat part of dose-response curve for local control Either extra 5 Gy is not needed, or shorter treatment course compensated for less dose due to less repopulation 40 Gy/15 fx confers lower normal tissue dose leading to less late toxicity Benjamin D Smith, ASTRO 2017
28 Kim KS, Shin KH et al, Radiat Oncol J 34:81-87, 2016
29 Issues to be solved Regional nodal irradiation Tumor bed boost Heart DCIS Biologic subtype Tumor grade
30 Regional nodal irradiation and boost RMH/GOC START A START B Canadian No. of pts Age <50 yrs 30.3% 23% 21% 25% Stage T1-3N0-1 T1-3N0-1 T1-3N0-1 T1-2N0 pn0 40% 69% 74% 100% HG III - 28% 23% 19% BCS 100% 85% 92% 100% CTx 13.9% 35% 22% 11% RNI 21% 14% 7% 0% Boost 75% 61% 39% 0% Boost dose 14 Gy/7fx 10 Gy/5fx 10 Gy/5fx - Holloway CL. The breast 19:163-7, 2010
31 Arm and Shoulder effects in START Trials - Regional Nodal Irradiation Haviland et al. Radiother Oncol 2018;126:
32 PMRT Phase II Trial Khan et al. J Clin Oncol 2018;126:
33 Heart Major coronary events increased linearly with mean heart dose Darby SC. NEJM 368(11): , 2013
34 Heart Hypofractionated adjuvant RT did not significantly increase the risk of cardiac mortality. Marhin W. IJROBP 69:483-9, 2007
35 DCIS, retrospective data. Conventional 50Gy/25fx (n=104) AWBI 42.4Gy/16fx or 40Gy/16fx+12.5Gy boost (n=162) Williamson D. Radiot Oncol 95: , 2010
36 Loco-regional relapse free survival after BCS Basal HER2 Breast cancer is known to have heterogeneous subtypes Different α/β ratio (cell survival curve) between subtypes? Voduc, JCO 28:1684, 2010
37 Molecular subtype Canadian trial Bane AL, Ann Oncol, 25: 993,2014
38 Tumor grade Whelan TJ, NEJM 362:513, 2010 Central Path Review (N=989 of 1234 enrolled patients) Bane AL, Ann Oncol, 25: 993,2014
39 START Trials: Subgroup Analysis Haviland et al. Lancet Oncol 2013;14:
40 Korean Data
41
42 JY Kim, KH Shin. IJROBP 87: , 2013
43
44 Comparison with other studies This study START A START B Canadian Patient, n Stage T1-2 N0-1 T1-3aN0-1 T1-3aN0-1 T1-2 N0 Median F/U 4.9 years 5.1 years 6 years 12 years Dose schedule 39 Gy / 13 F + 9 Gy / 3F (Boost) A : 39 Gy / 13F B : 41.6 Gy / 13F C : 50 Gy / 25F A : 40 Gy / 15 F B : 50 Gy / 25F A : 42.5 Gy / 16 F B : 50 Gy / 25F Boost RT 100% 61% 43% 0% Results 5-year LRR - 1.4% 5-year LRR - 39 Gy : 5.2% Gy : 3.5% - 50 Gy : 3.6% 5-year LRR - 40 Gy : 2.2% - 50 Gy : 3.3% 10-year LRR Gy : 6.2% - 50 Gy : 6.7%
45 This study This study
46 Cosmesis RMH/GOC START A START B Canadian Total dose(gy) / fractionation 50/25 39/ /13 50/25 39/ /13 50/25 40/15 50/ /16 Excellent/Good Cosmesis or no change (%) (5 year) This study 39/13+boost 9/ (3 year)
47 Skin toxicity Total dose(gy) / fractionation Moderate /Marked Induration (%) 5 yr 10 yr Skin toxicity (%) 5 yr 10 yr RMH/GOC 50/25 39/ / START A 50/25 39/ / (HR) START B 50/25 40/ (HR) Canadian 50/ / This study 39/13+boost 9/3 2.7 (3yr) Grade 1 (3yr) Hyperpigmentation 1.8 breast pain 7.1 induration 2.7
48 Retrospective Data in Korea pt1-2n0-1 breast-conserving surgery hypofractionated RT: 39 Gy/13fx National Cancer Center conventional RT: 50.4 Gy/28fx Seoul National University Hospital 379 patients in each group Lee et al. Medicine(Baltimore) 2016;95:e3320.
49 Lee et al. Medicine(Baltimore) 2016;95:e3320.
50 BCS+RT, pt1-2n0-1m0 AWBI (39Gy+ boost, NCC) n=330 CWBI (50.4Gy+boost, SNUH) n=330 S-W Lee, KH Shin. Oncotarget 7: , 2016
51 Hazard ratios for IBTR
52 Skin toxicities
53 ASTRO Guideline [2011] 50 yrs or older at diagnosis pt1-2n0 breast-conserving surgery w/o systemic chemotherapy acceptable dose heterogeneity 50 Gy/25 fx in 5 wks 42.5 Gy/16 fx in 3 wks Smith et al. Int J Radiat Oncol Biol Phys 2011;81:59-68.
54 According to Period Medicare + Medicaid data: 65 yr & BCS + WBRT Gillespie et al. Int J Radiat Oncol Biol Phys 2016;96:
55 According to Chemotherapy NCDB data: 50 yr & pt1-2n0 & WBRT alone Diwanji et al. Breast Cancer Res Treat 2017;165:
56 ASTRO Guideline [2018] Original WBI guideline was published in In June 2015, the Guidelines Subcommittee formed a work group to evaluated the guideline for updating. The proposal to develop a new guideline was approved by the ASTRO Board of Directors in October Not yet published
57 Nov. 2016
58 There is no indication to use more than 15 fractions for the breast, chest wall or nodal areas. Strong support (70-90% support) DCIS, regional nodal irradiation : favor hypofx Nov. 2016
59
60 Looking to the future, why consider conventionally fractionated breast radiotherapy at all? At present, there are more limited data available on tumor control and toxic effects outcomes with hypofractionated irradiation for patients with ductal carcinoma in situ and for patients receiving regional nodal irradiation. Nonetheless, the mounting evidence supporting hypofractionation can no longer be ignored. With comparable tumor control, lower costs, and reduced morbidity, hypofractionation should be strongly considered for the majority of patients with earlystage disease. JAMA Oncol J 1: , 2017
61 Patterns of Care Survey in Korea Shared decision (N=11) No (N=41) Yes (N=23) Physician s choice (N=12) Unpublished data
62 Patient preference Hoopes DJ et al. 1,807 patients respond 10% 62% 28% IJROBP 82: , 2011
63 RCT s: Treatment Scheme Fisher et al. J Clin Oncol 2014;32:
64 SNUH AWBI: Scheme Conventional RT 60.4 Gy / daily dose 1.8Gy / 33 fractions /6.6 weeks Whole breast (28 fx) week Tumor bed boost (5 fx) Hypofractionated RT 50.1 Gy / daily dose 2.7 Gy / 19 fractions / 3.8 weeks Whole breast (15 fx) week Tumor bed boost (4 fx)
65 Thank you
How can we Personalize RT as part of Breast-Conserving Therapy?
How can we Personalize RT as part of Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School Disclosures I have no COI disclosures
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationPost-Lumpectomy Radiation Techniques and Toxicities
Post-Lumpectomy Radiation Techniques and Toxicities Laura Willson, MD Abbott Northwestern Hospital Dept. of Radiation Oncology February 2, 2019 Learning Objectives How radiation therapy works Standard
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationHypofractionated Radiotherapy for breast cancer: Updated evidence
2 rd Bangladesh Breast Cancer Conference, Dhaka, December 2017 Hypofractionated Radiotherapy for breast cancer: Updated evidence Tabassum Wadasadawala Associate Professor of Radiation Oncology Tata Memorial
More informationHypofractionated RT in Cervix Cancer. Anuja Jhingran, MD
Hypofractionated RT in Cervix Cancer Anuja Jhingran, MD Hypofractionated RT in Cervix Cancer: Clinicaltrials.gov 919 cervix trials 134 hypofractionated RT trials Prostate, breast, NSCLC, GBM 0 cervix trials
More information03/14/2019. Postmastectomy radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D.
radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D. Division of Radiation Oncology Allegheny Health Network Cancer Institute Professor of Radiation Oncology
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationRadiation Therapy for the Oncologist in Breast Cancer
REVIEW ARTICLE Chonnam National University Medical School Sung-Ja Ahn, M.D. Adjuvant Tamoxifen with or without in Patients 70 Years of Age with Stage I ER-Positive Breast Cancer: Efficacy Outcomes (10
More informationPrinciples of breast radiation therapy
ANZ 1601/BIG 16-02 EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Healthcare Network Philadelphia, PA Professor
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationRadiation Treatment for Breast. Cancer. Melissa James Radiation Oncologist August 2015
Radiation Treatment for Breast Cancer Melissa James Radiation Oncologist August 2015 OUTLINE External Beam Radiation treatment. (What is Radiation, doctor?) Role of radiation. (Why am I getting radiation,
More informationBreast cancer: Clinical evidence. of new treatments. Aero academy Conference Innovation and Safety. Patients Come First
Breast cancer: Clinical evidence of new treatments Aero academy Conference Innovation and Safety Patients Come First January 26 & 27, 2018 Lisbon, Portugal Disclosure & Disclaimer An honorarium is provided
More informationState of the Art in 2000 State of the Art today Gazing forward
2010 Buschke Lecture: The Relationship between Local Recurrence and Survival in Breast Cancer Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School
More informationACCELERATED BREAST IRRADIATION EVOLVING PARADIGM FOR TREATMENT OF EARLY STAGE BREAST CANCER
ACCELERATED BREAST IRRADIATION EVOLVING PARADIGM FOR TREATMENT OF EARLY STAGE BREAST CANCER KHANH NGUYEN, MD, MA DEPARTMENT OF RADIATION ONCOLOGY BAYHEALTH CANCER CENTER BREAST CANCER STATISTICS Most common
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Medical Center Philadelphia, PA Professor (Adjunct)
More informationIntraoperative. Radiotherapy
Intraoperative Radiotherapy ROBERTO ORECCHIA UNIVERSITY of MILAN & EUROPEAN INSTITUTE of ONCOLOGY & CNAO FOUNDATION Breast Cancer Brescia, 30th September 2011 IORT, very selective technique to intensify
More informationBruno CUTULI Policlinico Courlancy REIMS. WORKSHOP SULL IRRADIAZIONE MAMMARIA IPOFRAZIONATA Il carcinoma duttale in situ
Bruno CUTULI Policlinico Courlancy REIMS WORKSHOP SULL IRRADIAZIONE MAMMARIA IPOFRAZIONATA Il carcinoma duttale in situ XXI CONGRESSO AIRO GENOVA 22.11.2011 INTRODUCTION Due to wide diffusion of mammography,
More informationPost-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)
Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and Women s Hospital Harvard Medical School Conclusions When considering PMRT, use both
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationIORT What We ve Learned So Far
IORT What We ve Learned So Far The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationConsensus Guideline on Accelerated Partial Breast Irradiation
Consensus Guideline on Accelerated Partial Breast Irradiation Purpose: To outline the use of accelerated partial breast irradiation (APBI) for the treatment of breast cancer. Associated ASBS Guidelines
More informationBreast cancer. (early and advanced) Radiotherapy
Breast cancer (early and advanced) Radiotherapy Need for RT. ESTRO-HERO estimation Tumor site RT courses 2012 Increase in number 2025 Increase in rate (%) Breast 396,891 40,524 10.2 Lung 315,197 56,558
More informationBreast Cancer Radiotherapy: Clinical challenges in 2011 from a European Perspective. Dr DA WHEATLEY CONSULTANT ONCOLOGIST ROYAL CORNWALL HOSPITAL
Breast Cancer Radiotherapy: Clinical challenges in 2011 from a European Perspective Dr DA WHEATLEY CONSULTANT ONCOLOGIST ROYAL CORNWALL HOSPITAL Radiotherapy in Early Breast Cancer Why do we do it? Who
More informationCase Conference: Post-Mastectomy Radiotherapy
Case Conference: Post-Mastectomy Radiotherapy Outline - Case Intro Guidelines Studies - Case Conclusion Summary Outline Case Intro to PMRT Guidelines Studies Case conclusion Summary Outline - Case Intro
More informationRecent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective
Recent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective Tokyo-West Tokushukai Hospital Department of Breast Oncology Tokyo-West Tokushukai Hospital, Tokyo, Japan Kaz Sato, MD,
More informationAcute and late adverse effects of breast cancer radiation: Two hypo-fractionation protocols
ORIGINAL ARTICLES Acute and late adverse effects of breast cancer radiation: Two hypo-fractionation protocols Mohamed Abdelhamed Aboziada 1, Samir Shehata 2 1 Department of Radiation Oncology, South Egypt
More informationHypofractionated radiotherapy for breast cancer: too fast or too much?
Editorial Hypofractionated radiotherapy for breast cancer: too fast or too much? Vassilis E. Kouloulias 1, Anna G. Zygogianni 2 1 2nd Department of Radiology, Radiotherapy unit, Attikon University Hospital,
More information2017 Topics. Biology of Breast Cancer. Omission of RT in older women with low-risk features
2017 Topics Biology of Breast Cancer Early-stage HER2+ breast cancer-can we avoid RT? Prediction tools for locoregional recurrence Omission of RT in older women with low-risk features Local-Regional Recurrence
More informationCurrent Status of Accelerated Partial Breast Irradiation. Julia White MD Professor, Radiation Oncology
Current Status of Accelerated Partial Breast Irradiation Julia White MD Professor, Radiation Oncology I have no disclosures relative to the presented material Agenda ABPI Timeline APBI by Method Clinical
More informationCorporate Medical Policy
Corporate Medical Policy Breast Brachytherapy for Accelerated Partial Breast Radiotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: breast_brachytherapy_for_accelerated_partial_breast_radiotherapy
More informationEarly Stage Breast Cancer
Local-Regional Management of Early Stage Breast Cancer Meena S. Moran, MD Associate Professor, Yale University School of Medicine Disclosure I have no conflicts of interest to disclose. Learning Objectives
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationEvaluating the Z011 study and how local-regional therapy for early breast cancer may change
Evaluating the Z011 study and how local-regional therapy for early breast cancer may change Karen Hoffman, M.D., M.H.Sc., M.P.H. Dept of Radiation Oncology The University of Texas MD Anderson Cancer Center
More informationRADIOTHERAPY IN BREAST CANCER :
RADIOTHERAPY IN BREAST CANCER : PAST, PRESENT, FUTURE Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Cancer Institute Narayana Superspecialty Hospital Breast cancer is the classic paradigm
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Accelerated Breast Irradiation and Brachytherapy Boost Page 1 of 23 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Accelerated Breast Irradiation and Brachytherapy
More informationPartial Breast Irradiation for Breast Conserving Therapy
To Radiate or Not? Is APBI the Right Compromise Solution? Partial Breast Irradiation for Breast Conserving Therapy Julia White MD Professor, Radiation Oncology Agenda Role of radiotherapy in breast conservation
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Accelerated Breast Irradiation and Brachytherapy Boost Page 1 of 27 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Accelerated Breast Irradiation and Brachytherapy
More informationSSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer
SSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer Dr. Yvonne Tsang St. Paul s Hospital Introductions Breast-conserving
More informationDisclosure. Objectives 03/19/2019. Current Issues in Management of DCIS Radiation Oncology Considerations
Current Issues in Management of DCIS Radiation Oncology Considerations Fariba Asrari, M.D. Director. Johns Hopkins Breast Center at Green Spring Station Department of Radiation Oncology & Molecular Sciences
More informationBy Rufus Mark, MD, Gail Lebovic, MD, Valerie Gorman, MD, Oscar Calvo, PhD. TABLE 1 EARLY STAGE BREAST CANCER RANDOMIZED TRIALS M vs.
EVOLUTION OF BREAST CONSERVATION RADIATION TREATMENT TECHNIQUES IN BREAST CANCER : FROM 6 WEEKS TO 3 WEEKS TO 1 WEEK TO 1 DAY AND FROM WHOLE BREAST TO PARTIAL BREAST By Rufus Mark, MD, Gail Lebovic, MD,
More informationFirst results from the clinically controlled randomized DBCG PBI trial
First results from the clinically controlled randomized DBCG PBI trial BV Offersen 1, MS Thomsen 1, HM Nielsen 1, EH Jacobsen 2, M Berg 2, MH Nielsen 3, E Lorenzen 3, L Stenbygaard 4, I Jensen 4, AN Petersen
More informationBreast Conservation Therapy
May 18, 2018 Breast Conservation Therapy One Treatment No Longer Fits All Presenter: Paul B. Fowler, MD Radiation Oncology, MGSH/MUMH 1 Objectives: 1. Define stages of breast cancer that are candidates
More informationObjectives Intraoperative Radiation Therapy for Early Stage Breast Cancer
Objectives Intraoperative Radiation Therapy for Early Stage Breast Cancer Cristina Lopez-Peñalver, MD, FACS October 11, 2014 Disclosures I have no relevant commercial relationships to disclose. Discuss
More informationSlide 1. Slide 2. Slide 3 History of Nurse Navigator
Slide 1 The Nurse Navigators role in Early Stage Breast Cancer, and Development of Tailored Treatment Plan Laura Ochoa, RN, ANP-BC, Ph.D. Slide 2 Barnes Jewish Hospital at Washington University Slide 3
More informationASTRO Refresher Course 2016 Breast Cancer
ASTRO Refresher Course 2016 Breast Cancer Jennifer R. Bellon, M.D. Dana-Farber Cancer Institute Associate Professor of Radiation Oncology Harvard Medical School I have no relevant conflicts of interest
More informationEvolution of Regional Nodal Management of Breast Cancer
Evolution of Regional Nodal Management of Breast Cancer Bruce G. Haffty, MD Director (Interim) Rutgers Cancer Institute of New Jersey Professor and Chair Department of Radiation Oncology Rutgers, The State
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationProtocol of Radiotherapy for Breast Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Breast Cancer Indication of radiotherapy Indications for Post-Mastectomy Radiotherapy (1) Axillary lymph node 4 positive (2) Axillary lymph node 1-3 positive:
More informationWhat are Adequate Margins of Resection for Breast-Conserving Therapy?
What are Adequate Margins of Resection for Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School What are Adequate Margins
More informationGenomic Profiling of Tumors and Loco-Regional Recurrence
1 Genomic Profiling of Tumors and Loco-Regional Recurrence Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationAdvances in Breast Cancer
Advances in Breast Cancer Developed in collaboration Learning Objectives Upon completion, participants should be able to: Apply genomic medicine to treatment decisions for patients with HR+/HER2- early
More informationRecent Update in Surgery for the Management of Breast Cancer
Recent Update in Surgery for the Management of Breast Cancer Wonshik Han, MD, PhD Professor, Department of Surgery, Seoul National University College of Medicine Chief of Breast Care Center, Seoul National
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationCa in situ e ormonoterapia. Discussant : LORENZA MARINO
Ca in situ e ormonoterapia Discussant : LORENZA MARINO Ca in situ e ormonoterapia Quali fattori di rischio? Radioterapia? Ormonoterapia? BCS Recurrence rates (FUP 13-20y) Cuzick, Lancet Oncol.2011; 12(1):
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationAnthony E. Dragun, M.D. Associate Professor Vice Chair and Residency Program Director U of L SOM, Dept. of Radiation Oncology
Anthony E. Dragun, M.D. Associate Professor Vice Chair and Residency Program Director U of L SOM, Dept. of Radiation Oncology KCR 29 th Annual Advanced Cancer Registrars Workshop 10 September 2015 1. What
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
- Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationNew Technologies in Radiation Oncology. Catherine Park, MD, MPH Advocate Good Shepherd Hospital
New Technologies in Radiation Oncology Catherine Park, MD, MPH Advocate Good Shepherd Hospital Breast Radiation Early Stage Breast Cancer Whole Breast Radiation Delivered to the whole breast Boost to the
More informationRecent Advances in Breast Radiotherapy
Recent Advances in Breast Radiotherapy Dr Anna Kirby Consultant Clinical Oncologist 2 The Royal Marsden Overview: Key innovations 1. 2D to 3D planning 2. Hypofractionation 3. Intensity modulated radiotherapy
More informationAdjuvant Radiotherapy
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Radiotherapy Adjuvant Radiotherapy (RT) Versions 2002 2012: Souchon / Blohmer / Friedrichs / Göhring / / Janni / Möbus
More informationIs Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease?
Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease? Mylin A. Torres, MD Director, Glenn Family Breast Center Louis and Rand Glenn Family Chair in Breast
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationRadiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin
1 Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin Disclosures: none Agenda 1. ACOSOG Z-11: Another perspective
More informationUniversity of Groningen. Local treatment in young breast cancer patients Joppe, Enje Jacoba
University of Groningen Local treatment in young breast cancer patients Joppe, Enje Jacoba IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationIndications for Post- Mastectomy Radiotherapy and Considerations in Treatment Planning
Indications for Post- Mastectomy Radiotherapy and Considerations in Treatment Planning Lori J. Pierce M.D., FASTRO Professor of Radiation Oncology University of Michigan Comprehensive Cancer Center Post-Mastectomy
More informationAccelerated Partial Breast Irradiation
Accelerated Partial Breast Irradiation OSCO/OU Stephenson Cancer Center Saturday, March 5, 2016 Robert Kuske, MD, FAACE Founder, Medical Director Arizona Breast Cancer Specialists Scottsdale, Arizona 1
More informationRadiotherapy and Oncology
Radiotherapy and Oncology 106 (2013) 15 20 Contents lists available at SciVerse ScienceDirect Radiotherapy and Oncology journal homepage: www.thegreenjournal.com Review Accelerated fractionation with a
More informationM D..,., M. M P.. P H., H, F. F A.. A C..S..
Implications of NSABP B-32 and Loco-Regional Therapy Considerations After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H, F.A.C.S. Professor of Surgery Northeastern Ohio Medical University Medical
More informationMultidisciplinary management of breast cancer
Multidisciplinary management of breast cancer C. Polgár 1,2 1 National Institute of Oncology 2 Semmelweis University Department of Oncology Incidence of breast cancer in Hungary 2014 Female population
More informationBreast Cancer: Management of the Axilla in Greg McKinnon MD FRCSC SON Vancouver Oct 2016
Breast Cancer: Management of the Axilla in 2016 Greg McKinnon MD FRCSC SON Vancouver Oct 2016 No Disclosures Principle #1 There is no point talking about surgical therapy in isolation. From a patient
More informationClinical Case Conference Melanoma
Clinical Case Conference Melanoma Epidemiology ~60,000 cases and 8,000 deaths per year in US Caucasian:African American = 10:1 15% arise from existing nevi 91% are cutaneous 15% are LN+ at presentation
More informationClinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience
Original Article Clinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience Rachel Murray 1, Fantine Giap 2, Ray Lin
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:10.22034/APJCP.2016.17.11.4819 RESEARCH ARTICLE Comparison of Conventional and Hypofractionated Radiotherapy in Breast Cancer Patients in Terms of 5-Year Survival, Locoregional Recurrence, Late Skin
More informationSpeaker s Bureau. Travel expenses. Advisory Boards. Stock. Genentech Invuity Medtronic Pacira. Faxitron. Dune TransMed7 Genomic Health.
Management of DCIS Shawna C. Willey, MD, FACS Professor of Surgery, Georgetown University Director, Medstar Regional Breast Health Program Chief, Department of Surgery Medstar Georgetown University Hospital
More informationAccelerated Radiation Treatment for Early Stage Breast Cancer. update and perspective
Accelerated Radiation Treatment for Early Stage Breast Cancer update and perspective School of Breast Oncology Atlanta, 11/2012 Douglas W. Arthur, M.D. Professor Traditional Whole Breast Irradiation WBI
More informationWhat is an Adequate Lumpectomy Margin in 2018?
What is an Adequate Lumpectomy Margin in 2018? Stuart J. Schnitt, M.D. Brigham and Women s Hospital, Dana-Farber Cancer Institute, and Harvard Medical School Boston, MA None Disclosures Topics Current
More informationClinical Trials of Proton Therapy for Breast Cancer. Andrew L. Chang, MD 張維安 Study Chair
Clinical Trials of Proton Therapy for Breast Cancer Andrew L. Chang, MD 張維安 Study Chair AndrewLChangMD@gmail.com Disclosure Proton Center Development Corporation Scripps San Diego Proton Therapy Center
More informationTrends in the Use of Implantable Accelerated Partial Breast Irradiation Therapy for Early Stage Breast Cancer in the United States
Trends in the Use of Implantable Accelerated Partial Breast Irradiation Therapy for Early Stage Breast Cancer in the United States A THESIS SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY
More informationHypofractionation and positioning in breast cancer radiation. John Hardie, M.D., Ph.D. November 2016
Hypofractionation and positioning in breast cancer radiation John Hardie, M.D., Ph.D. November 2016 At McFarland/MGMC we treat early stage breast cancer with 42.4 Gy in 16 fractions, in the prone position.
More informationLong-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
The new england journal of medicine original article Long-Term Results of Radiation Therapy for Breast Cancer Timothy J. Whelan, B.M., B.Ch., Jean-Philippe Pignol, M.D., Mark N. Levine, M.D., Jim A. Julian,
More informationHypo- versus normofractionated radiation therapy of early breast cancer in the randomized DBCG HYPO trial
Hypo- versus normofractionated radiation therapy of early breast cancer in the randomized DBCG HYPO trial BV Offersen 1, HM Nielsen 1, EH Jacobsen 2, MH Nielsen 3, M Krause 4, L Stenbygaard 5, I Mjaaland
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationThe Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
More informationMinesh Mehta, Northwestern University. Chicago, IL
* Minesh Mehta, Northwestern University Chicago, IL Consultant: Adnexus, Bayer, Merck, Tomotherapy Stock Options: Colby, Pharmacyclics, Procertus, Stemina, Tomotherapy Board of Directors: Pharmacyclics
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationPartial Breast Irradiation using adaptive MRgRT
Partial Breast Irradiation using adaptive MRgRT Shyama Tetar, radiation-oncologist VUmc Amsterdam 15-12-2017 5 th Vumc SBRT symposium 2017 Current practice Breast conserving treatment (BCT) Breast conserving
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationHypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials
Review Article Breast Care 2015;10:240 245 DOI: 10.1159/000439007 Published online: August 19, 2015 Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis
More informationAccelerated Radiation Treatment for Early Stage Breast Cancer. update and perspective
Accelerated Radiation Treatment for Early Stage Breast Cancer update and perspective School of Breast Oncology Atlanta, 11/2013 Douglas W. Arthur, M.D. Professor Traditional Whole Breast Irradiation WBI
More informationThe Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer
The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer Le défi des traitements locorégionaux individualisés pour les patientes présentant un cancer du sein
More informationInvasive Breast Cancer
Invasive Breast Cancer Eileen Rakovitch MD MSc FRCPC Sunnybrook Health Sciences Centre Medical Director, Louise Temerty Breast Cancer Centre LC Campbell Chair in Breast Cancer Research Associate Professor,
More informationThe Role of a Boost Radiation Dose in Patients with Negative Re-Excision Findings
24 The Open Breast Cancer Journal, 2011, 3, 24-28 Open Access The Role of a Boost Radiation Dose in with Negative Re-Excision Melanie C. Smitt and Kathleen C. Horst * Department of Radiation Oncology,
More informationThe Management of Breast Cancer 2015 ASTRO Spring Refresher
The Management of Breast Cancer 2015 ASTRO Spring Refresher Gary M. Freedman, M.D. Associate Professor Disclosure I have no conflicts of interest to disclose. 2 Learning Objectives Apply knowledge of randomized
More information